JPS58144750A - Determination of iron in serum - Google Patents
Determination of iron in serumInfo
- Publication number
- JPS58144750A JPS58144750A JP2865882A JP2865882A JPS58144750A JP S58144750 A JPS58144750 A JP S58144750A JP 2865882 A JP2865882 A JP 2865882A JP 2865882 A JP2865882 A JP 2865882A JP S58144750 A JPS58144750 A JP S58144750A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- iron
- solution
- ascorbic acid
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 28
- 210000002966 serum Anatomy 0.000 title claims abstract description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 31
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 26
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 26
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 26
- 239000007800 oxidant agent Substances 0.000 claims abstract description 10
- 238000004040 coloring Methods 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 102000004316 Oxidoreductases Human genes 0.000 claims description 12
- 108090000854 Oxidoreductases Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- JROAZQFKSSYEBL-TWNXTNBYSA-L disodium;5-[(z)-(3-carboxy-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)-(2,6-dichlorophenyl)methyl]-3-methyl-2-oxidobenzoate Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(=O)C(C)=C\C1=C(C=1C(=CC=CC=1Cl)Cl)/C1=CC(C)=C(O)C(C([O-])=O)=C1 JROAZQFKSSYEBL-TWNXTNBYSA-L 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 2
- 238000004445 quantitative analysis Methods 0.000 claims 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 abstract 4
- 239000012295 chemical reaction liquid Substances 0.000 abstract 3
- SWIRFWUEJODNRG-LTCKWSDVSA-L disodium;(2s)-2-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SWIRFWUEJODNRG-LTCKWSDVSA-L 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960002098 sodium folate Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 5
- 239000001230 potassium iodate Substances 0.000 description 5
- 235000006666 potassium iodate Nutrition 0.000 description 5
- 229940093930 potassium iodate Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LJJZKMDEQVYRJX-UHFFFAOYSA-N 4,5,6-tripyridin-2-yltriazine Chemical compound N1=CC=CC=C1C1=NN=NC(C=2N=CC=CC=2)=C1C1=CC=CC=N1 LJJZKMDEQVYRJX-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】 この@明は血清鉄の定量法に関する。[Detailed description of the invention] This @ Ming relates to a method for quantifying serum iron.
血清中の鉄の測定は、溶血性貧血、悪性貧血、再生不良
性貧血、急性肝炎、鉄欠乏性貧血などの検査として臨床
上重要視されている。とくに、最近の医学から、鉄欠乏
性貧血疾患の際に、鉄の生体キレートであるトランスフ
ェリンが増加することが知られておに、血清鉄とともに
、総鉄結合能(?IBO)の測定は、診断上価値が鳥い
・生体内では、食餌として摂取された鉄は、小腸内で吸
収され、腸壁で7ポフエリチンにより 、Fe (1)
から浦に酸化され、フエリチ/と結合し丸形で存在する
。血中に入る際には、Fe CLKR元され、さらに血
中で酸化されFed)と′&)、トランスフェリンとの
結合を行なう。このようにして、吸収され丸鉄は、生体
内のあらゆる場所に送もれ、恒常性を保っている。生体
内の鉄は、ヘモグロビン鉄、建オダロビ/鉄、貯蔵鉄、
血清鉄として存在し、通常、血清鉄の濃度は、成人男子
90〜140μI/di、成人女子80〜120 Il
l/(11である。Measurement of iron in serum is clinically important as a test for hemolytic anemia, pernicious anemia, aplastic anemia, acute hepatitis, iron deficiency anemia, and the like. In particular, it is known from recent medical science that transferrin, a biological chelate of iron, increases in iron-deficiency anemia diseases. Diagnostic value: In the living body, iron ingested as a diet is absorbed in the small intestine and is converted to Fe(1) by 7 poferritin in the intestinal wall.
It is oxidized to Karaura and exists in a round shape combined with Ferriti/. When it enters the blood, it is converted into Fe CLKR, further oxidized in the blood, and binds to Fed) and '&) and transferrin. In this way, the absorbed round iron is sent to all parts of the body and maintains homeostasis. Iron in the body is hemoglobin iron, Kenodarobi iron, stored iron,
It exists as serum iron, and the normal concentration of serum iron is 90 to 140 μI/di in adult men and 80 to 120 μI/di in adult women.
l/(11.
従来Ojk清鉄測定法には、比色法、原子微光法、発光
法(IOP)、電極法などがある。これらの中“で、自
動生化学分析装置に応用する場合、比色法がもつとも簡
便で、他の生化学分析項目と同様に分析することも可能
で、日常検査には最適である。Conventional Ojk clear iron measuring methods include colorimetric method, atomic microphotometry, optical emission method (IOP), and electrode method. Among these methods, when applied to automatic biochemical analyzers, the colorimetric method is the simplest and can be analyzed in the same way as other biochemical analysis items, making it ideal for routine testing.
比色法で血清鉄の分析を行なう場合、通常、っぎのよう
な操作が必要である。When performing serum iron analysis using a colorimetric method, operations such as those described above are usually required.
(1)トランスフェリンから鉄を分離し、除たん白する
。(1) Separate iron from transferrin and remove protein.
(2)Fe[)からFe (1)K還ycスル。(2) Fe[) to Fe (1) K-ring yc sul.
f3)Fe(i)を発色させ、測定する。f3) Colorize Fe(i) and measure.
従来法では、(3)の発色剤として、パソ7エナンスロ
リン、トリピリジルトリアジン、フェロジンなどが用い
られてきたが、これらはいずれもFe(1)K対して特
異的に反応するため、上記のような操作が必要であり、
まえ、直接法により測定する場合感度が低いため、微量
血清を用いる最近の自動分析装置では、測定が困難であ
った。In the conventional method, paso7enanthroline, tripyridyltriazine, ferrozine, etc. have been used as the coloring agent in (3), but since all of these react specifically with Fe(1)K, they cannot be used as described above. operations are required,
Previously, due to the low sensitivity of direct measurements, it was difficult to measure with modern automated analyzers that use trace amounts of serum.
我々は、新しく開発された高感度の鉄キレート発色剤、
クロマズロールB(以下、OABと略す。We have developed a newly developed highly sensitive iron chelate color former,
Chromazrol B (hereinafter abbreviated as OAB).
図IK構造式を示す)を用いた直接法により、0L−1
2で血清鉄の測定を行なったところ、良好な結果を得た
(島津評論38巻2号27〜3゜頁(1981年怠
し−1ながら、このCABを用いる直接調定法において
も、アスコルビン酸が共存すると鉄の定量に誤差を生じ
、とのアスコルビン酸は輸液された患者中アスコルビン
酸複合剤を投与された患者!
にみられるため、従来法では問題があっ九。この発明は
、かかる患者の血清を使用しても、正確にかつ簡便に鉄
含量を定量しうる方法を提供するものである。0L-1 was obtained by a direct method using
2, serum iron was measured, and good results were obtained (Shimadzu Review Vol. 38, No. 2, pp. 27-3 (1981). The coexistence of ascorbic acid causes errors in the determination of iron, and ascorbic acid is seen in patients who receive infusions and patients who have been administered ascorbic acid complex drugs.Therefore, there are problems with the conventional method. The purpose of the present invention is to provide a method that can accurately and easily quantify iron content even when using blood serum.
そして、この発明による測定法の特徴は、血清とOAB
の反応処理に際し、アスコルビン酸オキシダーゼ溶液ま
たは酸化剤溶液を添加することにある。それによってア
スコルビン酸の負影響が避けられる。The characteristics of the measurement method according to this invention are that serum and OAB
During the reaction treatment, an ascorbic acid oxidase solution or an oxidizing agent solution is added. The negative effects of ascorbic acid are thereby avoided.
この発明に用いられる酸化剤としては、ヨク酸カリウム
、ヨウ酸ナトリウムなどが挙げられる。Examples of the oxidizing agent used in this invention include potassium iocate and sodium iorate.
アスコルビン酸オキシダーゼは、市販のものt用いるこ
とができる。これら酸化剤ま九は、アスコルビン酸オキ
シダーゼの反応液中での添加濃度は血清中のアスコルビ
ン酸の濃度によって異なるが。Commercially available ascorbic acid oxidase can be used. The concentration of these oxidizing agents in the ascorbic acid oxidase reaction solution varies depending on the concentration of ascorbic acid in the serum.
一般にアスコルビンII 100sF//% I 、”
’fスマル(ン酸オキシダーゼ666z/#(好ましい
。この添加濃度において、通常の血清(アスシルピ/酸
複合剤の服用などをしていない患者からの血清)K対し
てもこの発明の定量法は十分適用可能である。Generally Ascorbine II 100sF//% I,”
'Fsmar(acid oxidase 666z/#) (preferable. At this added concentration, the assay method of the present invention is sufficient even for normal serum (serum from a patient who is not taking an ascilpiate/acid complex) K. Applicable.
この発明において用いるクロマズロールB発色試薬の添
加濃度は、公知の条件を利用すればよい。The concentration of the chromazurol B coloring reagent used in this invention may be determined using known conditions.
さらに、後述するように、この発明の方法においてはア
スコルビン酸オキシダーゼ溶液または酸化剤溶液と血清
との接触は、一般にクロマズロールB発色試薬と少なく
とも同時かその前が好ましい。詳しくは実験の部で説明
される。Further, as described below, in the method of the present invention, it is generally preferred that the ascorbic acid oxidase solution or the oxidizing agent solution be brought into contact with the serum at least simultaneously with or before the chromazurol B coloring reagent. Details are explained in the experimental section.
実験の部
1、試薬
クロマズロールBナトリウム塩(株式会社同仁化学研究
所m>。臭化セチルトリメチルアンモニウム(以下OT
MAと略す)、無水酢酸ナトリウム、塩化ナトリウム、
無水酢酸、クエン酸、クエン酸ナトリウム、ヨウ素酸カ
リウム、アスコルビン酸オキシダーゼ(ペーリ/ガーマ
/ハイム社製ビオケンカ)。(いずれも和光特級試薬使
用)。Experimental part 1, reagent Cromazurol B sodium salt (Dojindo Chemical Laboratory Co., Ltd.). Cetyltrimethylammonium bromide (hereinafter OT)
abbreviated as MA), anhydrous sodium acetate, sodium chloride,
Acetic anhydride, citric acid, sodium citrate, potassium iodate, ascorbic acid oxidase (Biokenka manufactured by Peri/Germa/Heim). (Both use Wako special grade reagents).
2、試薬調整
(a)OAB$11;0AB0.1ftlOOdlxy
ラスコに秤取し、蒸留水で100mとする(2.0mm
ol / l )
(b)O’l’MA溶液:OTMAO,:1t100s
Z/スフラスコに秤取し、蒸留水で100s/とする(
8.2mmol / l )。2. Reagent adjustment (a) OAB$11; 0AB0.1ftlOOdlxy
Weigh it in a lasco and add distilled water to make it 100m (2.0mm).
ol/l) (b) O'l'MA solution: OTMAO,: 1t100s
Weigh it into a Z/ flask and add distilled water to make it 100s/
8.2 mmol/l).
(0) 酢酸緩衡液;無水酢酸ナトリウム251と、
塩化ナトリウム110fを蒸留水に浴解し、無水酢酸8
.0 m?を加え、全体を1000mとす21(PH4
,7□5)。(0) Acetic acid buffer; anhydrous sodium acetate 251;
Dissolve 110f of sodium chloride in distilled water, and dissolve 8% of acetic anhydride.
.. 0 m? 21 (PH4
,7□5).
(由発色試薬:OAB溶[60s/KO’l’MA溶液
90gItを加え、混合後、酢酸緩債液を加え、全体を
100011tとする。(Coloring reagent: Add 90g of OAB solution [60s/KO'l'MA solution, and after mixing, add acetic acid solution to bring the total to 100011t.
(6) マスク試薬;クエン酸(1水和物)17fと
、クエン酸ナトリウム(2水塩)35Mt−蒸留水で溶
解し100IItとする。(6) Mask reagent: 17f of citric acid (monohydrate) and 35Mt of sodium citrate (dihydrate) - Dissolved in distilled water to make 100IIt.
検体ブランク測定用発色試薬:発色試薬とマスク試薬を
30:1の割合で混合する。Coloring reagent for sample blank measurement: Mix coloring reagent and mask reagent at a ratio of 30:1.
(0ヨウ素酸カリウム溶液;ヨウ素酸カリウム0.31
0.015M−リン酸バッファーPH6,8100g/
中に溶解し、反応試薬中濃度0.311Iになるように
調整した。最終反応濃度Fi0.044−とした。(0 potassium iodate solution; potassium iodate 0.31
0.015M-phosphate buffer PH6, 8100g/
The concentration in the reaction reagent was adjusted to 0.311I. The final reaction concentration Fi was set at 0.044-.
(2)アスコルビン酸オキシダーゼ溶液;アスコルビン
醒オキシダーゼは0.1M−リ/#ナトリウムバッファ
ーpH5,6で希釈し、反応試薬中濃度を666u/l
Kなるように調整した。最終反応濃度は133u/lと
した。(2) Ascorbic acid oxidase solution; ascorbic acid oxidase was diluted with 0.1 M-Li/# sodium buffer pH 5,6, and the concentration in the reaction reagent was 666 u/l.
I adjusted it so that it was K. The final reaction concentration was 133 u/l.
なお、試薬の調整に用いるガラス器具類は、4〜6N塩
酸に一夜間浸して除鉄し、蒸留水で十分にすすぎ、汚染
されないように注意して乾燥しておく。また調整用の水
も純度の高いイオン交換水か蒸留水を使用する。Note that the glassware used for preparing the reagents is soaked overnight in 4-6N hydrochloric acid to remove iron, thoroughly rinsed with distilled water, and carefully dried to avoid contamination. Also, use highly purified ion-exchanged water or distilled water for conditioning.
3、装置
島津自動生化学分析装置0L−12形、島津原子吸光/
フレーム分光光度計AA−640−13形を用いた。3. Equipment Shimadzu automatic biochemical analyzer 0L-12 type, Shimadzu atomic absorption/
A flame spectrophotometer AA-640-13 type was used.
4、分析条件、および操作
0L−12において同時に測定可能な12チヤンネルの
うち、5チヤンネルと9チヤンネルをそれぞれ鉄分折用
、検体ブランク用とした。試薬送液用ディスペンサは、
流路における鉄汚染を避けるため、テフロン材質の電磁
弁が用いられているボ/プを使用し丸。4. Analysis Conditions and Procedures Of the 12 channels that can be measured simultaneously under 0L-12, channels 5 and 9 were used for iron analysis and as a sample blank, respectively. The dispenser for reagent delivery is
In order to avoid iron contamination in the flow path, a valve with a Teflon material solenoid valve is used.
(1)重版プール血清に所定量のアスコルビン酸を添加
して検体とした(アスコルビン酸の添加量は図1参照)
。(1) A predetermined amount of ascorbic acid was added to the reprinted pooled serum to prepare the sample (see Figure 1 for the amount of ascorbic acid added).
.
この血清検体50μノを純水200μmとと−に反応管
に分注する。50 μm of this serum sample and 200 μm of pure water are dispensed into a reaction tube.
一方アスコルビン酸オキシダーゼ溶液t−第1試薬とし
、この0.3 dを検体分注後15秒後(第2列目)に
分注した。さらに発色試薬(前記2.d)項に記載を第
2試薬とし、その1.5s/l−第1試薬分注後0秒(
同時分注)、30秒(第4列目)、60秒(第6列目)
後に分注した。On the other hand, ascorbic acid oxidase solution t-1st reagent was used, and 0.3 d of this was dispensed 15 seconds after dispensing the sample (second row). Furthermore, the coloring reagent (2.d) above is described as the second reagent, and its 1.5 s/l - 0 seconds after dispensing the first reagent (
simultaneous dispensing), 30 seconds (4th column), 60 seconds (6th column)
It was later dispensed.
史に、ブランクチャンネルでは上記の第2試薬の分注の
際にマスク試薬を同時分注した。Historically, in the blank channel, the mask reagent was simultaneously dispensed when the second reagent was dispensed.
(軸) 上ffiのアスコルビン酸オキシダーゼ溶液
の代りに、ヨウ素酸カリウム溶液を第1試薬とし、上記
の(1)と同様に分注した。(Axis) Instead of the ascorbic acid oxidase solution in the upper ffi, a potassium iodate solution was used as the first reagent and dispensed in the same manner as in (1) above.
(ilil) IlI光では、発色した溶液の最大吸
収波長は630Imn −あるが、この−j定では6
28Imと670Imの二波長を用いた。その理由は、
0L−12の検出器の関係と吸収曲線がブロードであり
、また試薬プラ/りの吸光度が大きいために670Im
を対象側波長として選んだ。(ilil) With IlI light, the maximum absorption wavelength of a colored solution is 630Imn -, but with this -j constant, it is 630Imn -.
Two wavelengths of 28Im and 670Im were used. The reason is,
The detector relationship and absorption curve of 0L-12 are broad, and the absorbance of the reagent plastic is large, so 670 Im
was selected as the target wavelength.
なお、測定データの検体プラ/り補正は、つぎの(1)
式に基づいて自動的に行なわれる。In addition, the sample value correction of measurement data is as follows (1)
This is done automatically based on the formula.
(1) (!=K・(ムドムtb )−(St/Sl)
・(A!−ム2b))ここで、0:濃度(uf/dl)
、に:1度換算係数、A1:分析用チャンネル測定値、
ムlb ”分析用チャンネル試薬ブランク、ム!:検体
ブランク用チャンネル測定値、ム、b=検体ブランク用
チャンネル試薬ブランク、8!/ 81 :感度比、(
Al、Alb%A!、AteいずれもmAbg単位)キ
ャリフレージョンは市販コ、ントロール血清ハイラント
’l (Lot、No、0368WOOdム)を用いて
行なつ九。濃度Cを208μf/al (デュポンaC
&による測定値)として求めたに値は−2,2101(
μf/dJ−mAbs)であった。(1) (!=K・(mudomtb)−(St/Sl)
・(A!-mu2b)) Here, 0: Concentration (uf/dl)
, N: 1 degree conversion factor, A1: Analysis channel measurement value,
Mlb "Analysis channel reagent blank, M!: Channel measurement value for sample blank, M, b = Channel reagent blank for sample blank, 8!/81: Sensitivity ratio, (
Al, Alb%A! Calibration was performed using a commercially available control serum Hylant'l (Lot, No. 0368 WOODM). Concentration C is 208 μf/al (Dupont aC
The value obtained as -2,2101 (measured value by &) is -2,2101 (
μf/dJ-mAbs).
5、分析納本
(1)゛ アスコルビン酸オキシダーゼ添加血清検体
を横軸に、Fe測定値を縦軸にとシ、アスコルビン酸の
除去効果を示したのが図1である。5. Analysis Report (1) Figure 1 shows the ascorbic acid removal effect, with the ascorbic acid oxidase-added serum specimen on the horizontal axis and the Fe measurement value on the vertical axis.
比較のため純水を分注した結果を図1中に破線で示し、
第1試薬と同時に第2試薬を加えた場合、30秒後、1
分後に加えた場合の効果を示しているO
1九、これらの添加条件に対応した同時再塊性のデータ
は表1の通りである。For comparison, the results of dispensing pure water are shown by the broken line in Figure 1.
If the second reagent is added at the same time as the first reagent, after 30 seconds, 1
Table 1 shows the effect of O 19 when added after 1 minute, and the simultaneous re-agglomeration data corresponding to these addition conditions are shown in Table 1.
表1 同時再現性 (1)
以上の結果から、共存するアスコルビン酸による影響(
測定値への負の影響)を充分除去できることが判明しえ
。Table 1 Simultaneous reproducibility (1) From the above results, the influence of coexisting ascorbic acid (
It turns out that the negative influence on measured values can be sufficiently eliminated.
まえ上記の条件で社、第2試薬の分注を第1試薬の分注
後30秒で行うのが最良であることが分る0
(II) Wつ木酸カリウムの添加
除去効果は図2に示し、同時再現性を表2に示す。Under the above conditions, it is found that it is best to dispense the second reagent 30 seconds after dispensing the first reagent. Table 2 shows the simultaneous reproducibility.
表2 同時再現性(2)
以上の結果から、ヨウ素酸カリウム添加による共存アス
コルビン酸の負影譬が充分避けられることが明らかであ
るが、上記条件下で社第2試薬の分注は同時あるiは3
0秒後がIIkILであった。Table 2 Simultaneous reproducibility (2) From the above results, it is clear that the addition of potassium iodate sufficiently avoids the negative effects of coexisting ascorbic acid. i is 3
0 seconds later was IIkIL.
図1と図2は、血清中におけるアスコルビン酸の共存に
対し、アスコルビン酸オキシダーゼ又は曹つ木酸カリウ
ム添加による鉄含量測定値に対する影響を示す図である
。縦軸は鉄量で、横軸はアスコルビン酸添加量を示す。FIGS. 1 and 2 are diagrams showing the influence of the addition of ascorbic acid oxidase or potassium sulfate on the measured iron content with respect to the coexistence of ascorbic acid in serum. The vertical axis shows the amount of iron, and the horizontal axis shows the amount of ascorbic acid added.
Claims (1)
に、アスコルビン酸オキシダーゼ溶液またFi酸化剤溶
液を添加し1反応液の吸光度を測定して血清中の鉄分を
定量することよりなる血清鉄の定量法。 2、アスコルビン酸オキシダーゼ溶液または酸化剤溶液
の添加と同時ま九は添加約30#後にクロマズロールB
発色試薬を添加する特許請求の範囲第1項記載の定量法
。[Claims] 1. When treating a serum sample with a Cromazurol B coloring reagent, add an ascorbic acid oxidase solution or a Fi oxidizing agent solution, 1. Measure the absorbance of the reaction solution, and quantify the iron content in the serum. A method for quantifying serum iron consisting of: 2. At the same time as adding ascorbic acid oxidase solution or oxidizing agent solution, add Chromazurol B after about 30 minutes of addition.
The quantitative method according to claim 1, wherein a coloring reagent is added.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2865882A JPS58144750A (en) | 1982-02-23 | 1982-02-23 | Determination of iron in serum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2865882A JPS58144750A (en) | 1982-02-23 | 1982-02-23 | Determination of iron in serum |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS58144750A true JPS58144750A (en) | 1983-08-29 |
Family
ID=12254599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2865882A Pending JPS58144750A (en) | 1982-02-23 | 1982-02-23 | Determination of iron in serum |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58144750A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925570A (en) * | 1991-12-25 | 1999-07-20 | Iatron Laboratories, Inc. | Method of measuring metals in samples of living body |
US6627448B1 (en) * | 1999-10-04 | 2003-09-30 | Reference Diagnostics, Inc. | Analyte-binding assay |
-
1982
- 1982-02-23 JP JP2865882A patent/JPS58144750A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925570A (en) * | 1991-12-25 | 1999-07-20 | Iatron Laboratories, Inc. | Method of measuring metals in samples of living body |
US6627448B1 (en) * | 1999-10-04 | 2003-09-30 | Reference Diagnostics, Inc. | Analyte-binding assay |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cholak et al. | Determination of lead in biological and related material by atomic absorption spectrophotometry | |
Kessler et al. | An automated procedure for the simultaneous determination of calcium and phosphorus | |
JPH0113062B2 (en) | ||
JPH09511575A (en) | Cyanide-free reagents and methods for the determination of hemoglobin | |
EP1881328A1 (en) | Method of determining iron concentration | |
US5387524A (en) | Method for quantitative flow injection analysis of metals in body fluids | |
US4393142A (en) | Assay method and reagent for the determination of chloride | |
US4105408A (en) | Urea assay | |
JPS58144750A (en) | Determination of iron in serum | |
CA2071001A1 (en) | Reagent and methods for serum iron assay | |
JP3220378B2 (en) | Method and reagent for quantification of total protein | |
US4095948A (en) | Determination of uric acid | |
Moorehead et al. | An automated micromethod for determination of serum glucose, with an improved o-toluidine reagent | |
Klein et al. | Application of Fe (II)-5-pyridyl benzodiazepin-2-ones to the determination of serum iron and iron-binding capacity | |
US6355489B1 (en) | Method for the determination of oxygen-centered free radicals | |
US4826773A (en) | Method and reagent for the quantitative determination of phosphorous in serum and urine | |
US3792044A (en) | Method for determining glucose with o-toluidine reagent containing an arsenic compound | |
Bertrand et al. | Determination of serum methemalbumin by second-derivative spectroscopy | |
Goodwin | Direct estimation of serum iron and unsaturated iron binding capacity in a single aliquot | |
JP2001099826A (en) | Complex coloring method and coloring reagent | |
JP2632989B2 (en) | Method for measuring unsaturated iron binding ability | |
JPH04361160A (en) | Measurement of protein | |
Liu et al. | Interference of sodium azide with measurement of serum uric acid by the direct acid ferric reduction procedure. | |
JPH02122267A (en) | Hemoglobin quantitative reagent kit and hemoglobin quantitative method using the same | |
JP3614951B2 (en) | Methods and reagents for measuring enzyme activity |